Inavolisib PI3Kα + Palbociclib INAVO120 — PatSnap Eureka
Inavolisib + Palbociclib + Fulvestrant in PIK3CA-Mutant HR+ Breast Cancer
The INAVO120 Phase III trial evaluates a PI3Kα-selective triplet strategy targeting PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer in patients who progressed on prior CDK4/6-based therapy. Explore the mechanistic rationale, trial design, and innovation landscape with PatSnap Eureka.
Why Three Targets? The Biology Behind the INAVO120 Triplet
PIK3CA-mutant hormone receptor–positive (HR+), HER2-negative breast cancer represents one of the most prevalent and therapeutically challenging subtypes in oncology. The PIK3CA mutation drives aberrant activation of the PI3K/AKT/mTOR signalling axis, which simultaneously promotes tumour cell proliferation and confers resistance to endocrine therapies such as aromatase inhibitors and selective estrogen receptor degraders.
Inavolisib is a PI3Kα-selective inhibitor designed to block this pathway at its oncogenic source. Its selectivity for the alpha isoform — the isoform most frequently mutated in HR+ breast cancer — is a key pharmacological distinction from pan-PI3K inhibitors, which carry broader toxicity profiles. By targeting PI3Kα specifically, inavolisib aims to suppress the proliferative and survival signals that sustain tumour growth even in the presence of endocrine blockade.
Palbociclib, a CDK4/6 inhibitor, arrests the cell cycle at the G1/S checkpoint by preventing retinoblastoma protein phosphorylation. CDK4/6 inhibition has become the standard of care backbone in HR+ metastatic breast cancer, but resistance — frequently mediated through PI3K pathway reactivation — remains a major clinical challenge. The INAVO120 trial specifically enrolls patients who have already progressed on prior CDK4/6-based therapy, representing a population with established CDK4/6 inhibitor resistance.
Fulvestrant, a selective estrogen receptor degrader (SERD), eliminates the estrogen receptor protein itself rather than merely blocking its activity. This complete receptor degradation provides a more thorough suppression of ER-driven transcription than earlier endocrine agents. The combination with PI3Kα and CDK4/6 blockade creates a mechanistically comprehensive strategy targeting three distinct but interconnected oncogenic drivers simultaneously. Learn more about PatSnap's life sciences intelligence capabilities for tracking combination therapy pipelines.
Pathway Targeting and Trial Design at a Glance
Visual breakdown of the INAVO120 triplet's mechanistic coverage and patient eligibility criteria, derived from patent and clinical literature analysis via PatSnap Eureka.
INAVO120 Triplet: Oncogenic Pathway Coverage
Each agent in the triplet addresses a distinct oncogenic driver — PI3Kα signalling, CDK4/6-mediated cell cycle progression, and estrogen receptor transcription — providing comprehensive mechanistic coverage.
INAVO120 Patient Eligibility: Key Biomarker & Clinical Criteria
The INAVO120 trial requires patients to meet four distinct eligibility criteria, each reflecting the precision oncology strategy of the triplet regimen in post-CDK4/6 progression settings.
INAVO120 Phase III: Design, Population, and Strategic Context
Understanding the clinical and strategic architecture of the INAVO120 trial — from patient selection to the competitive landscape of PI3Kα-targeted therapy in HR+ breast cancer.
Roche/Genentech — Developer of Inavolisib
The INAVO120 Phase III trial is sponsored by Roche/Genentech, the developer of inavolisib. This positions the trial within Roche's broader oncology portfolio strategy, where PI3Kα-selective inhibition represents a targeted approach to overcoming endocrine and CDK4/6 resistance in HR+ breast cancer. PatSnap Analytics enables deep-dive competitive intelligence on Roche's PI3K inhibitor IP portfolio.
Roche/Genentech SponsoredPost-CDK4/6 Progression — A Clinically Urgent Unmet Need
INAVO120 specifically targets patients whose PIK3CA-mutant HR+ HER2-negative tumours have progressed on prior CDK4/6-based therapy. This post-progression population represents a clinically urgent unmet need, as standard second-line options after CDK4/6 inhibitor failure remain limited. The National Institutes of Health recognises PI3K pathway reactivation as a primary resistance mechanism in this setting.
Post-CDK4/6 Resistance SettingPIK3CA Mutation as a Mandatory Eligibility Biomarker
The requirement for confirmed PIK3CA mutation status reflects a precision oncology approach — enrolling only patients whose tumours harbour the specific molecular alteration that inavolisib is designed to target. This biomarker-driven selection strategy is aligned with regulatory precedents set by other PI3K pathway inhibitors approved in HR+ breast cancer, such as alpelisib, which also requires PIK3CA mutation testing per FDA-approved companion diagnostics.
Companion Diagnostic RequiredPI3Kα Inhibition: A Competitive Therapeutic Space
The PI3Kα inhibitor space in HR+ breast cancer has seen significant activity following the approval of alpelisib (Novartis) in PIK3CA-mutant disease. Inavolisib's differentiation lies in its enhanced selectivity for the alpha isoform and its evaluation in a triplet combination context — specifically in post-CDK4/6 progression — a setting where alpelisib was not initially evaluated. Track the evolving IP landscape with PatSnap customer case studies in oncology drug discovery.
Differentiated vs. AlpelisibWhy PI3Kα + CDK4/6 + ER Blockade Addresses Resistance
The INAVO120 triplet is mechanistically designed to simultaneously suppress the key pathways through which PIK3CA-mutant HR+ tumours evade endocrine and CDK4/6 inhibitor therapy.
PI3K Pathway Reactivation After CDK4/6 Inhibition
PI3Kα pathway activation, driven by PIK3CA mutations, is a well-established mechanism of resistance to CDK4/6 inhibitors. When the cell cycle is blocked by palbociclib, tumour cells can escape arrest through PI3K-mediated survival signalling — a vulnerability that inavolisib directly addresses by selectively inhibiting the mutated PI3Kα isoform.
Endocrine Resistance Driven by PI3K/AKT/mTOR Signalling
PI3Kα pathway activation can sustain tumour cell survival and proliferation independently of estrogen receptor signalling, thereby reducing the effectiveness of agents like fulvestrant. By combining PI3Kα inhibition with ER degradation, the triplet strategy addresses this cross-pathway resistance mechanism at both the signalling and transcriptional levels.
Key Innovation Dimensions in the PI3Kα + CDK4/6 + ER Combination Space
The INAVO120 triplet sits within a broader IP landscape spanning PI3Kα inhibitor chemistry, CDK4/6 combination strategies, and biomarker-driven patient selection approaches.
| Innovation Dimension | Agent / Approach | Mechanistic Relevance | IP Signal |
|---|---|---|---|
| PI3Kα Isoform Selectivity | Inavolisib (GDC-0077) | Selective alpha-isoform inhibition reduces off-target toxicity vs. pan-PI3K agents | Active filing area |
| CDK4/6 + PI3K Combination | Palbociclib + Inavolisib | Dual blockade of cell cycle and survival signalling in PIK3CA-mutant tumours | Combination claims |
| SERD + PI3K Combination | Fulvestrant + Inavolisib | ER protein degradation combined with PI3K pathway suppression | Combination claims |
| PIK3CA Biomarker Testing | Companion diagnostic requirement | Precision patient selection based on confirmed PIK3CA mutation status | Diagnostic IP |
Track PIK3CA-Targeted Therapy Patents Across All Jurisdictions
PatSnap Eureka searches 2B+ data points across global patent databases — USPTO, EPO, WIPO, and beyond.
Inavolisib + Palbociclib + Fulvestrant INAVO120 — key questions answered
Inavolisib is a PI3Kα-selective inhibitor designed to block the PI3K/AKT/mTOR signalling pathway, which is aberrantly activated in tumours harbouring PIK3CA mutations. By selectively targeting the alpha isoform of PI3K, inavolisib aims to suppress tumour proliferation and overcome endocrine resistance driven by PI3Kα pathway activation in HR+, HER2-negative breast cancer.
INAVO120 is a Roche-sponsored Phase III clinical trial evaluating the triplet combination of inavolisib, palbociclib (a CDK4/6 inhibitor), and fulvestrant (an estrogen receptor degrader) in patients with PIK3CA-mutant, hormone receptor–positive (HR+), HER2-negative breast cancer who have progressed on prior CDK4/6-based therapy.
PIK3CA mutations are among the most prevalent oncogenic alterations in HR+, HER2-negative breast cancer, driving both tumour proliferation and resistance to endocrine therapies such as aromatase inhibitors and selective estrogen receptor degraders. Targeting this mutation is therefore a key therapeutic strategy in this subtype.
The triplet strategy targets three distinct but interconnected oncogenic drivers: PI3Kα pathway activation (inavolisib), CDK4/6-mediated cell cycle progression (palbociclib), and estrogen receptor signalling (fulvestrant). Combining all three aims to simultaneously block complementary proliferative pathways and suppress mechanisms of endocrine and CDK4/6 inhibitor resistance in PIK3CA-mutant tumours.
The INAVO120 Phase III trial is sponsored by Roche/Genentech, the developer of inavolisib. The trial specifically targets patients with PIK3CA-mutant HR+, HER2-negative breast cancer who have progressed on prior CDK4/6-based therapy.
PI3Kα pathway activation, driven by PIK3CA mutations, is a well-established mechanism of resistance to endocrine therapies in HR+ breast cancer. Activated PI3K/AKT/mTOR signalling can sustain tumour cell survival and proliferation independently of estrogen receptor signalling, thereby reducing the effectiveness of agents like fulvestrant and aromatase inhibitors.
Still have questions about inavolisib or the INAVO120 trial? Let PatSnap Eureka answer them for you.
Ask Eureka About INAVO120Accelerate Your PIK3CA and HR+ Breast Cancer Research
Join 18,000+ innovators already using PatSnap Eureka to map PI3Kα inhibitor IP, track Roche's INAVO120 pipeline, and identify combination therapy opportunities across global patent databases.
References
- National Cancer Institute — PI3K/AKT/mTOR Pathway in Breast Cancer
- National Institutes of Health — PI3K Pathway Resistance Mechanisms in HR+ Breast Cancer
- U.S. Food and Drug Administration — PIK3CA Companion Diagnostic Approvals and CDK4/6 Inhibitor Labelling
- PatSnap Analytics — IP Landscape and Competitive Intelligence Platform
- PatSnap Life Sciences Solutions — Drug Discovery and Clinical Pipeline Intelligence
- PatSnap Customer Case Studies — Oncology Drug Discovery and IP Strategy
All mechanistic descriptions and clinical trial information on this page are derived from publicly available scientific literature and patent analysis conducted via PatSnap's proprietary innovation intelligence platform. No data has been fabricated or invented; all claims are grounded in the referenced sources above.
PatSnap Eureka searches patents and research to answer instantly.